Abstract

The reauthorization of the Prescription Drug User Fee Act (PDUFA)—a system where drug companies pay fees to FDA to support its process for reviewing applications for new drugs and biologicals—is “an extremely important step” for the agency, said Commissioner Andrew C. von Eschenbach.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call